Phillip Terry Meikle II - 04 Jun 2025 Form 4 Insider Report for Bone Biologics Corp (BBLG)

Reporting relationship: Director
Issuer ticker: BBLG
Reported as of: 04 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2025, 17:01:30 UTC
Prior SEC filing: 18 Oct 2024
Source filing: View source filing
Reporting owner signature: /s/ Phillip Meikle

Key filing fact

Phillip Terry Meikle II filed Form 4 for Bone Biologics Corp (BBLG) on 06 Jun 2025.

Key facts

This page summarizes Phillip Terry Meikle II's Form 4 filing for Bone Biologics Corp (BBLG).
1 reported transaction and 3 derivative rows are listed below.
Accepted by SEC: 06 Jun 2025, 17:01.

Change

Previous filing in this sequence was filed on 18 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002041874 Primary reporting owner

Meikle Phillip Terry II

Relationship: Director
Address: C/O BONE BIOLOGICS CORP,, 2 BURLINGTON WOODS DR. SUITE 100, BURLINGTON,
Signature: /s/ Phillip Meikle
Signature date: 06 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBLG transaction Derivative

Non-Employee Stock Option

Award

Transaction value: $0
Shares: +62,894
Change %
Price: $0.000000
Shares after: 62,894
Date: 04 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 62,894
Exercise price: $0.8800
Footnotes: F1

BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 28,185
Date: 04 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,185
Exercise price: $1.88
Footnotes: F2

BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 9
Date: 04 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9
Exercise price: $1.88
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

Footnote F2

This option was granted on 10/16/2024 and vests in equal installments on each of 12/17/2024, 3/19/2025, 6/19/2025 and 9/17/2025.

Footnote F3

This option is fully exercisable as of the date of this report.